ORCHPHARMA Orchid Pharma Q3 FY25 results (Oct–Dec 2024) and concall
Orchid Pharma reported a robust 15% YoY growth in total income for the first nine months of FY25, reaching INR710 crores, with PAT increasing by 26% to INR78 crores. Despite price corrections in key products, the company maintained healthy margins by prioritizing profitability over volume at reduced prices. Strategic projects like the 7ACA initiative are advancing, and the AMS division is in an investment phase, expected to become EBITDA accretive after another year.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 223 | 217 |
| EBITDA | 30 | 26 |
| Net profit | 27 | 21 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
